/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

R

Roger Echols

MP Technologies (United States)(US)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

178

Papers

7.1K

Citations

44

h-index

94

i10-index

Roger Echols is an academic researcher from MP Technologies (United States). The author has contributed to research in topics: Antibiotics Pharmacokinetics and Efficacy & Antibiotic Resistance in Bacteria & Antibiotic Use and Resistance. The author has an h-index of 44, co-authored 152 publications.

Research Topics

Antibiotics Pharmacokinetics and Efficacy Antibiotic Resistance in Bacteria Antibiotic Use and Resistance Pneumonia and Respiratory Infections Urinary Tract Infections Management

Papers by this author

works

Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial

2020 · The Lancet Infectious Diseases · 732 citations

https://doi.org/10.1016/s1473-3099(20)30796-9

Matteo Bassetti Roger Echols Yuko Matsunaga Mari Ariyasu

Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

2020 · The Lancet Infectious Diseases · 432 citations

https://doi.org/10.1016/s1473-3099(20)30731-3

Richard G. Wunderink Yuko Matsunaga Mari Ariyasu Philippe Clevenbergh

In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)

2018 · International Journal of Antimicrobial Agents · 188 citations

https://doi.org/10.1016/j.ijantimicag.2018.10.007

Krystyna M. Kazmierczak Masakatsu Tsuji Mark G. Wise Meredith Hackel

Reproducibility of broth microdilution MICs for the novel siderophore cephalosporin, cefiderocol, determined using iron-depleted cation-adjusted Mueller-Hinton broth

2019 · Diagnostic Microbiology and Infectious Disease · 118 citations

https://doi.org/10.1016/j.diagmicrobio.2019.03.003

Meredith Hackel Masakatsu Tsuji Yoshinori Yamano Roger Echols

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies

2022 · Clinical Infectious Diseases · 93 citations

https://doi.org/10.1093/cid/ciac078

Jean Francois Timsit Mical Paul Ryan K. Shields Roger Echols

Utilization of Colistin Versus β-Lactam and β-Lactamase Inhibitor Agents in Relation to Acute Kidney Injury in Patients with Severe Gram-Negative Infections

2021 · Infectious Diseases and Therapy · 14 citations

https://doi.org/10.1007/s40121-021-00556-x

Casey Doremus Stephen W. Marcella Bin Cai Roger Echols

Research topics

topics

Antibiotics Pharmacokinetics and Efficacy

Antibiotic Resistance in Bacteria

Antibiotic Use and Resistance

Pneumonia and Respiratory Infections

Urinary Tract Infections Management

Chat about Author

Papers

Chat

Click to start Chat